Originally, GBZ was developed, as a well-tolerated small α2-adrenergic receptor agonist that received FDA approval (Wytensin) for the treatment of hypertension (18), and represents therefore an interesting chemical compound to evaluate the therapeutic interest of targeting the eIF2α phosphorylation pathway, with the aim of controlling inflammation and prevent organs failure. Here, EIF2A is linked to hypertensive disorder.